Ron Chemmalakuzhy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ron Chemmalakuzhy has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Chloe Shay
Department of Pediatrics, Emory Children’s Center, Emory University, Atlanta, GA, USA
1 shared publication - Liwei Lang
Department of Oral Biology and Diagnostic Sciences, Dental College of Georgia, Augusta University, Augusta, GA 30912, USA
1 shared publication - Parth Thakkar
Department of Biology, College of Science and Mathematics, Augusta University, Augusta, GA, USA
1 shared publication - Xuli Wang
Department of Radiology and Imaging Sciences, School of Medicine, University of Utah, 201 Presidents Cir, Salt Lake City, UT, 84112, USA
1 shared publication - Yong Teng
Department of Hematology and Medical Oncology, Emory University, Atlanta, GA 30322, USA
1 shared publication - Yuanping Xiong
Department of Oral Biology, Dental College of Georgia, Augusta University, Augusta, GA, USA
1 shared publication
Latest Publications
- Open Access
- 20 June 2018
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 11 (1) , 1-13
Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib
Inhibition of metastasis of head and neck squamous cell carcinoma (HNSCC) is one of the most important challenges in cancer treatment. Src, a non-receptor tyrosine kinase, has been implicated as a key promoter in tumor progression and metastasis of HNSCC. However, Src therapy for HNSCC is limited by lack of efficient in vivo delivery and underlying mechanisms remain elusive. Src knockdown cells were achieved by lentiviral-mediated interference. Cell migration and invasion were examined by wound healing and Transwell assays. Protein levels were determined by Western blot and/or immunohistochemistry. The Src inhibitor saracatinib was loaded into self-assembling nanoparticles by the solvent evaporation method. An experimental metastasis mouse model was generated to investigate the drug efficacy in metastasis. Blockade of Src kinase activity by saracatinib effectively suppressed invasion and metastasis of HNSCC. Mechanistic assessment of the drug effects in HNSCC cells showed that saracatinib induced suppression of Src-dependent invasion/metastasis through downregulating the expression levels of Vimentin and Snail proteins. In tests in mice, saracatinib loaded into the novel multifunctional nanoparticles exhibited superior effects on suppression of HNSCC metastasis compared with the free drug, which is mainly attributed to highly specific and efficient tumor-targeted drug delivery system. These findings and advances are of great importance to the development of Src-targeted nanomedicine as a more effective therapy for metastatic HNSCC.
- 20 June 2018
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 11 (1) , 1-13
Open AccessCombating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib
Inhibition of metastasis of head and neck squamous cell carcinoma (HNSCC) is one of the most important challenges in cancer treatment. Src, a non-receptor tyrosine kinase, has been implicated as a key promoter in tumor progression and metastasis of HNSCC. However, Src therapy for HNSCC is limited by lack of efficient in vivo delivery and underlying mechanisms remain elusive. Src knockdown cells were achieved by lentiviral-mediated interference. Cell migration and invasion were examined by wound healing and Transwell assays. Protein levels were determined by Western blot and/or immunohistochemistry. The Src inhibitor saracatinib was loaded into self-assembling nanoparticles by the solvent evaporation method. An experimental metastasis mouse model was generated to investigate the drug efficacy in metastasis. Blockade of Src kinase activity by saracatinib effectively suppressed invasion and metastasis of HNSCC. Mechanistic assessment of the drug effects in HNSCC cells showed that saracatinib induced suppression of Src-dependent invasion/metastasis through downregulating the expression levels of Vimentin and Snail proteins. In tests in mice, saracatinib loaded into the novel multifunctional nanoparticles exhibited superior effects on suppression of HNSCC metastasis compared with the free drug, which is mainly attributed to highly specific and efficient tumor-targeted drug delivery system. These findings and advances are of great importance to the development of Src-targeted nanomedicine as a more effective therapy for metastatic HNSCC.